{"task_id": "4957e2409e4bf2c5", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 177/464)", "text": "d in CML and CMML\nMyeloproliferative Disorders\n165\n\n--- Page 187 ---\nDIAGNOSTIC AND PROGNOSTIC ISSUES (CONT\u2019D)\nPOLYCYTHEMIA RUBRA VERA\nmedian survival\n10 15 years, \u00051/100 transforms to CML, MF, AML\nCHRONIC\nMYELOGENOUS\nLEUKEMIA\nmedian\nsurvival 3 4 years, \u00051/2 transforms to AML\nESSENTIAL THROMBOCYTOSIS\nmedian survival\n10 15 years, \u00051/1000 transforms to AML\nMYELOFIBROSIS\nmedian survival 5 years, \u00051/10\ntransforms to AML\nMANAGEMENT\nPOLYCYTHEMIA RUBRA VERA\nphlebotomy 1 2/\nweek, aspirin, hydroxyurea\nCHRONIC MYELOGENOUS LEUKEMIA\n\u0002\nCHRONIC PHASE\nimatinib mesylate 400 800 mg PO\ndaily with cytogenetic response rate 63%, dasati\nnib and nilotinib may be used for imatinibresistant\ndisease. Allogeneic stem cell transplant is asso\nciated with 60 70% cure rate\n\u0002\nACCELERATED\nPHASE\nimatinib\nmesylate\n600 800 mg PO daily. Allogeneic stem cell trans\nplant is associated with 30 45% cure rate\n\u0002\nBLAST CRISIS\nimatinib mesylate 800 mg PO daily,\nplasmapheresis. Allogeneic stem cell transplant is\nassociated with 10 15% cure rate\n\u0002\nIMATINIB-RESISTANT CML\ndasitinib, nilotinib, and\nstem cell transplantation\nESSENTIAL THROMBOCYTOSIS\naspirin, anagre\nlide (# platelet via stabilizing membrane), hydro\nxyurea, alkylating agents, 32P\nMYELOFIBROSIS\nsplenectomy,\ninterferon\na,\nthalidomide\nTREATMENT ISSUES\nRESPONSE CRITERIA FOR CML\n\u0002\nHEMATOLOGICAL RESPONSE\n\u0002\nCOMPLETE RESPONSE\nWBC <10\u0003103/mL with no\nimmature granulocytes and <5% basophils, pla\ntelet <450\u0003103/mL, and non palpable spleen\nTREATMENT ISSUES (CONT\u2019D)\n\u0002\nPARTIAL RESPONSE\npersistence of immature cells\nin peripheral blood, platelets >450\u0003103/mL but\n<50% of pre treatment levels, or persistent sple\nnomegaly but <50% of pre treatment size\n\u0002\nCYTOGENIC RESPONSE (FISH detection of the Phila\ndelphia chromosome)\n\u0002\nCOMPLETE\n0% Ph+ cells\n\u0002\nPARTIAL\n1 35% Ph+ cells\n\u0002\nMAJOR\ncompleteandpartialcytogeneticresponse\n\u0002\nMINOR\n36 65% Ph+ cells\n\u0002\nMINIMAL\n66 95% Ph+ cells\n\u0002\nMOLECULAR RESPONSE (bcr abl transcript detection\nby RT PCR)\n\u0002\nCOMPLETE\nnegative\n\u0002\nMAJOR\nbcr abl to control gene ratio <0.1 (3 log\ndecrease in bcr abl transcript in peripheral blood)\nDEFINITION OF TREATMENT FAILURE FOR CML\nPATIENTS ON IMATINIB THERAPY\nMonths\nSuboptimal\nFailure\n3\n< CHR\nNo HR\n6\n< PCGR\n< CHR, no CGR\n12\n< CCGR\n< PCGR\n18\n< MMR\n< CCGR\nAnytime\nACA, loss of\nMMR\nLoss of CHR or\nCCGR\nwhere HR=hematologic response, CHR=complete\nhematologic response, CGR=cytogenetic response,\nPCGR=partial cytogenetic response, CCGR=complete\ncytogenetic\nresponse,\nMMR=major\nmolecular\nresponse, ACA=additional chromosomal abnormality\nMONITORING FOR CHRONIC MYELOGENOUS LEUKE\nMIA\nbone marrow annually, quantitative PCR every 3\nmonths (repeat test in 4 weeks if >0.5 log increase)\nIMATINIB RESISTANCE\nbcr abl mutations, over\nexpression or amplification of bcr abl\nAcute Myelogenous Leukemia\nNEJM 1999 341:14\nHEMATOLOGIC MALIGNANCIES OVERVIEW\nMYELO\nbone marrow. Myeloproliferative disor\nders (PRV, CML, ET, and MF) involve cell accumula\ntion, while myelodysplastic disorders involve abnor\nmal bone marrow cell growth. Both disorders have\nrisk of transformation to acute myeloid leukemia\nMYELOID\nneutrophils,\nmonocytes,\nmacro\nphages, eosinophils, basophils, mast cells, erythro\ncytes, platelets, and their precursors. Myeloid\nmalignancies include AML and CML\nHEMATOLOGIC MALIGNANCIES OVERVIEW (CONT\u2019D)\nLYMPHOID\nB cells, T cells, natural killer cells.\nLymphoid malignancies include ALL, CLL, and all\nlymphomas\nLEUKEMIA\nmalignant cells in blood and/or bone\nmarrow. May be myeloid (AML, CML) or lymphoid*\n(LL/ALL, SLL/CLL) in origin. Myeloid leukemia sel\ndom presents in lymph nodes\n\u0002\nACUTE LEUKEMIA\ninvolves immature blast cells.\nMore aggressive course\n166\nAcute Myelogenous Leukemia", "text_length": 3665, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 177/464)", "type": "chunk", "chunk_index": 176, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.488961", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.489893", "status": "complete", "chunks_added": 2}